ICOS
Executive Summary
Seattle-based biotech startup is currently in the process of a private placement offering which is expected to be completed in June. Venture capitalists Issac and David Blech are the principal financiers and Paine Webber is handling the placement. Founded in the fall of 1989, the company is headed by three major biotech execs: Chairman of the Board George Rathmann, PhD, (currently chairman of Amgen); President and CEO Robert Nowinski, PhD, (former VP Bristol Myers and founder of Genetics Systems); and Science Director Christopher Henney, PhD, (cofounder of Immunex). The company's focus will be the development of biotech and pharmaceutical therapeutics for the treatment of inflammatory diseases.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.